La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MAIA Biotechnology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MAIA Biotechnology..

MAIA Biotechnology (AMEX:MAIA) Azioni, Catena delle Opzioni

MAIA Biotechnology

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

MAIA Biotechnology Inc

Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) and Western Alliance Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) shares are trading lower in Monday&#8217;s after-hours session after the pair of regional banks reported financial results<a href="https://www.benzinga.com/pressreleases/25/04/n44910623/zions-bancorporation-national-association-reports-first-quarter-financial-results"> for the first quarter</a>.
Here&#8217;s a look at the headline numbers and key commentary from the reports.
ZION Q1 Earnings: Zions Bancorp reported first-quarter revenue of $795 million, missing analyst estimates of $797.07 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The bank reported first-quarter earnings of $1.13 per share, missing analyst estimates of $1.17 per share.
&#8220;Credit quality remained in very good shape during the quarter, with nonperforming assets stable compared with last quarter at&nbsp;0.51%&nbsp;of loans and leases and annualized net charge-offs of&nbsp;0.11%&nbsp;of loans and leases. At the same time, the&nbsp;outlook&nbsp;for the economy is perhaps more uncertain than it&#8217;s been in a number of years, clouded by the very real potential for negative impacts from tariffs and trade policy, both here and abroad,&#8221; said Harris Simmons, chairman and CEO of Zions Bancorp.
&#8220;We are nevertheless confident that our credit culture and practices and our strong reserves position us to manage through possible turbulence that might materialize in coming quarters.&#8221;
Zions Bancorp shares were down 3.71% after-hours, trading at $42.41 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. Zions&#8217; shares are down approximately 20% year-to-date.
WAL Q1 Earnings: Western Alliance reported first-quarter net revenue of $778 million, which appears to have come up short of <a href="https://www.benzinga.com/quote/WAL/earnings">analyst estimates</a>. The bank reported first-quarter earnings of $1.79 per share, beating estimates of $1.78 per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
&#8220;Western Alliance delivered solid&nbsp;first quarter&nbsp;results led by continued loan and deposit growth following the completion of our balance sheet repositioning efforts in 2024. Our deep segment and product expertise enables our business to adapt quickly to an evolving macro environment, while our fortified capital and liquidity levels position the firm to maintain business momentum and prudent credit risk management,&#8221; said Kenneth Vecchione, president and CEO of Western Alliance.
Western Alliance shares were moving lower, but faring better than Zions Bancorp shares at last check. The stock was down 1.36% after-hours, trading at $64 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44894658/deutsche-bank-standard-chartered-reportedly-looking-into-expanding-to-us-crypto-market">Deutsche Bank, Standard Chartered Reportedly Looking Into Expanding To US Crypto Market</a></li>
</ul>
<ul>
<li><a href="https://www.benzinga.com/etfs/currency-etfs/25/04/44903051/currency-volatility-spikes-as-central-banks-ponder-further-rate-cuts">Currency Volatility Spikes As Central Banks Ponder Further Rate Cuts</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/OLOZANO">OLOZANO</a>/Shutterstock.

Earnings

News

After-Hours Center

Movers

ZION

Regional Banks Zions, Western Alliance Move Lower Following Q1 Earnings: Key Highlights

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) has outperformed the market over the past 10 years by 1.42% on an annualized basis producing an average annual return of 10.71%. Currently, Globus Medical has a market capitalization of $9.77 billion. 
Buying $1000 In GMED: If an investor had bought $1000 of GMED stock 10 years ago, it would be worth $2,782.28 today based on a price of $71.01 for GMED at the time of writing.
<h3>Globus Medical's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745271027_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

GMED

$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

General

VSME

VS Media Holdings Files For Offering Of Minimum $5M To Maximum $15M Of Class A Shares

PFIS

Peoples Financial Services Files For Mixed Shelf Offering Of Up To $150M

Sprouts Farmers Market (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFM#NASDAQ">SFM</a>) has outperformed the market over the past 5 years by 36.18% on an annualized basis producing an average annual return of 48.86%. Currently, Sprouts Farmers Market has a market capitalization of $15.53 billion. 
Buying $1000 In SFM: If an investor had bought $1000 of SFM stock 5 years ago, it would be worth $7,407.94 today based on a price of $157.50 for SFM at the time of writing.
<h3>Sprouts Farmers Market's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745270110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Sprouts Farmers Market Stock In The Last 5 Years

Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) reported quarterly earnings of $2.69 per share which beat the analyst consensus estimate of $2.49 by 8.03 percent. This is a 6.92 percent decrease over earnings of $2.89 per share from the same period last year.

Earnings Beats

WTFC

Wintrust Finl Q1 EPS $2.69 Beats $2.49 Estimate

Guidance

ATKR

Atkore Sees Q2 2025 Adj. EPS $2.01-$2.08 Vs $1.40 Est.; Revenue $695M-$705M Vs $690.83M Est.; Maintains FY25 Adj. EPS Guidance Of $5.75-$6.85 Vs $6.09 Est.; Revenue $2.85B-$2.95B Vs $2.852B Est

<h3>Gainers</h3>
<ul>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) shares rose 23.3% to $0.95 during Monday's after-market session. The company's market cap stands at $6.2 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock rose 8.45% to $0.1. The company's market cap stands at $5.0 million. </li>
<li>Birks Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BGI#AMEX">BGI</a>) stock rose 6.87% to $0.95. The market value of their outstanding shares is at $18.2 million. </li>
<li>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) stock moved upwards by 4.99% to $0.86. The market value of their outstanding shares is at $19.5 million. </li>
<li>Duluth Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTH#NASDAQ">DLTH</a>) stock moved upwards by 4.97% to $1.9. The market value of their outstanding shares is at $68.3 million. </li>
<li>Flexsteel Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLXS#NASDAQ">FLXS</a>) shares rose 4.8% to $33.47. The market value of their outstanding shares is at $176.3 million. The company's, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) stock declined by 35.5% to $0.25 during Monday's after-market session. The company's market cap stands at $36.0 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock fell 17.43% to $0.34. The company's market cap stands at $11.9 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>EZGO Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZGO#NASDAQ">EZGO</a>) stock decreased by 11.39% to $0.32. The market value of their outstanding shares is at $1.8 million. </li>
<li>Ruanyun Edai Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYET#NASDAQ">RYET</a>) stock fell 6.85% to $6.94. The market value of their outstanding shares is at $234.2 million. </li>
<li>Lixiang Education Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXEH#NASDAQ">LXEH</a>) shares decreased by 5.93% to $2.7. The market value of their outstanding shares is at $3.1 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) stock fell 5.43% to $0.74. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGFV

DLTH

ECDA

EZGO

FLXS

HOFV

LXEH

MKDW

RYET

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) shares increased by 23.5% to $1.26 during Monday's after-market session. The company's market cap stands at $17.3 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) stock increased by 21.05% to $0.28. The company's market cap stands at $24.7 million. </li>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) shares moved upwards by 8.08% to $1.46. The company's market cap stands at $28.4 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 7.65% to $0.23. The company's market cap stands at $1.6 million. </li>
<li>Adial Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADIL#NASDAQ">ADIL</a>) shares increased by 7.63% to $0.72. The market value of their outstanding shares is at $4.7 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares rose 7.03% to $0.24. The company's market cap stands at $1.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares declined by 15.7% to $3.49 during Monday's after-market session. The company's market cap stands at $53.1 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) shares decreased by 11.42% to $0.62. The company's market cap stands at $1.5 million. </li>
<li>Medpace Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) stock decreased by 10.04% to $260.0. The market value of their outstanding shares is at $7.9 billion. The company's, Q1 earnings came out today. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) shares fell 9.19% to $5.24. The market value of their outstanding shares is at $7.7 million. </li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) shares declined by 7.57% to $1.1. The company's market cap stands at $2.7 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares declined by 6.8% to $0.41. The market value of their outstanding shares is at $13.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADIL

ANVS

CLDI

ENVB

MEDP

PRPO

PTIX

SXTC

XAIR

YCBD

ZVSA

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) shares moved upwards by 18.3% to $0.9 during Monday's after-market session. The company's market cap stands at $29.6 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) stock rose 6.21% to $2.05. The company's market cap stands at $68.5 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock moved upwards by 5.44% to $2.13. The company's market cap stands at $3.2 million. </li>
<li>Wheels Up Experience (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) stock increased by 4.98% to $0.82. The company's market cap stands at $572.3 million. </li>
<li>Pangaea Logistics Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANL#NASDAQ">PANL</a>) shares increased by 4.87% to $4.3. The market value of their outstanding shares is at $282.2 million. </li>
<li>Zoomcar Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) shares rose 4.83% to $3.25. The market value of their outstanding shares is at $2.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MingZhu Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) stock fell 11.7% to $0.91 during Monday's after-market session. The company's market cap stands at $69.7 million. </li>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) shares fell 9.53% to $3.23. </li>
<li>Energy Focus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EFOI#NASDAQ">EFOI</a>) stock decreased by 6.56% to $1.71. The company's market cap stands at $8.9 million. </li>
<li>DLH Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLHC#NASDAQ">DLHC</a>) stock fell 5.98% to $3.46. The company's market cap stands at $49.7 million. </li>
<li>Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) stock fell 5.59% to $3.55. The market value of their outstanding shares is at $828.6 million. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares declined by 5.13% to $0.2. The company's market cap stands at $6.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLIK

CTOS

DLHC

EFOI

GPUS

NEOV

OESX

PANL

RBNE

YGMZ

ZCAR

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) stock increased by 17.2% to $4.63 during Monday's after-market session. The company's market cap stands at $754.2 million. </li>
<li>Calix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) shares rose 13.98% to $37.9. The company's market cap stands at $2.5 billion. As per the press release, Q1 earnings came out today. </li>
<li>Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) shares increased by 7.07% to $1.36. The market value of their outstanding shares is at $322.6 million. </li>
<li>MMTEC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) shares moved upwards by 6.45% to $0.99. The company's market cap stands at $24.9 million. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) shares rose 5.93% to $1.04. The market value of their outstanding shares is at $21.9 million. </li>
<li>Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) stock rose 4.99% to $0.57. The company's market cap stands at $13.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) shares decreased by 12.8% to $1.3 during Monday's after-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Semilux International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SELX#NASDAQ">SELX</a>) stock fell 8.15% to $1.24. The market value of their outstanding shares is at $46.4 million. </li>
<li>Baijiayun Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RTC#NASDAQ">RTC</a>) shares decreased by 7.26% to $0.19. The company's market cap stands at $5.4 million. </li>
<li>SemiLEDs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEDS#NASDAQ">LEDS</a>) stock fell 6.17% to $1.98. The market value of their outstanding shares is at $14.2 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares declined by 6.0% to $11.13. The company's market cap stands at $110.9 million. </li>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) stock declined by 5.17% to $2.02. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CALX

FUFU

LEDS

MLGO

ORKT

SELX

SONM

VRAR

12 Information Technology Stocks Moving In Monday's After-Market Session

Medpace Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>) reported first-quarter financial results after market close on Monday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/04/b44910790/medpace-holdings-inc-reports-first-quarter-2025-results">from the quarter</a>.
<ul>
<li>Q1 Revenue: $558.57 million, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $527.15 million</li>
</ul>
<ul>
<li>Q1 EPS: $3.67, versus estimates of $3.06</li>
</ul>
Total revenue was up 9.3% on a year-over-year basis. New business awards totaled $500 million in the quarter, down 18.8% year-over-year. The company ended the period with a backlog of approximately $2.85 billion, down 2.1% year-over-year.
Medpace generated $125.8 million in cash flow from operations during the quarter. The company said it repurchased approximately 1.19 million shares for $389.8 million in the first quarter. Medpace&#8217;s board also authorized a $1 billion increase to the company&#8217;s buyback, bringing the total authorization up to approximately $1.34 billion.
The company ended the quarter with $441.4 million in cash and cash equivalents. 
Outlook: Medpace expects full-year 2025 revenue to be between $2.14 billion and $2.24 billion versus estimates of $2.15 billion. The company anticipates full-year earnings of $12.26 to $13.04 per share versus estimates of $12.27 per share. 
Medpace executives will further discuss the quarter on a call with investors and analysts Tuesday morning at 9 a.m. ET.
MEDP Price Action: <a href="http://benzinga.com/quote/medp">Medpace shares</a> were down 9.34% after-hours, trading at $262 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Check This Out: • <a href="https://www.benzinga.com/news/buybacks/25/04/44911715/calix-stock-jumps-on-strong-q1-earnings-100-million-buyback-increase">Calix Stock Jumps On Strong Q1 Earnings, $100 Million Buyback Increase</a>
Photo: <a href="https://www.shutterstock.com/g/mariakray">mariakray</a>/Shutterstock.

Biotech

Health Care

Medpace Holdings Reports Q1 Earnings, Shares Move Lower

SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) reported quarterly earnings of $0.67 per share which beat the analyst consensus estimate of $0.55 by 21.82 percent. This is a 36.73 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $46.84 million which beat the analyst consensus estimate of $46.23 million by 1.31 percent. This is a 16.79 percent increase over sales of $40.10 million the same period last year.

SMBK

SmartFinancial Q1 Adj $0.67 Beats $0.55 Estimate, Sales $46.84M Beat $46.23M Estimate

Phillips 66 Increases Quarterly Dividend From $1.15 to $1.20

During the last three months, 24 analysts shared their evaluations of Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>), revealing diverse outlooks from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">5</td>
<td align="right">12</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Nike, revealing an average target of $80.38, a high estimate of $115.00, and a low estimate of $64.00. A 4.45% drop is evident in the current average compared to the previous average price target of $84.12. 
<img src="https://www.benzinga.com/files/images/story/2025/1745269259_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Nike by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;---------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Sam Poser &#x7C;Williams Trading &#x7C;Lowers &#x7C;Buy &#x7C; $73.00&#x7C;$93.00 &#x7C; 
&#x7C;Anna Andreeva &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $70.00&#x7C;$90.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $64.00&#x7C;$75.00 &#x7C; 
&#x7C;Jim Duffy &#x7C;Stifel &#x7C;Maintains &#x7C;Hold &#x7C; $75.00&#x7C;$75.00 &#x7C; 
&#x7C;Alex Straton &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $70.00&#x7C;$72.00 &#x7C; 
&#x7C;Piral Dadhania &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $66.00&#x7C;$67.00 &#x7C; 
&#x7C;Matthew Boss &#x7C;JP Morgan &#x7C;Lowers &#x7C;Neutral &#x7C; $64.00&#x7C;$73.00 &#x7C; 
&#x7C;Jay Sole &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $66.00&#x7C;$73.00 &#x7C; 
&#x7C;Simeon Siegel &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $92.00&#x7C;$95.00 &#x7C; 
&#x7C;Joseph Civello &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $82.00&#x7C;$90.00 &#x7C; 
&#x7C;Ike Boruchow &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $85.00&#x7C;$90.00 &#x7C; 
&#x7C;Jonathan Komp &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $99.00&#x7C;$105.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $75.00&#x7C;$80.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $80.00&#x7C;$84.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Alex Straton &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $72.00&#x7C;$74.00 &#x7C; 
&#x7C;Randal Konik &#x7C;Jefferies &#x7C;Raises &#x7C;Buy &#x7C; $115.00&#x7C;$75.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Robert Drbul &#x7C;Guggenheim &#x7C;Maintains &#x7C;Buy &#x7C; $110.00&#x7C;$110.00 &#x7C; 
&#x7C;Tom Nikic &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $84.00&#x7C;$84.00 &#x7C; 
&#x7C;Paul Lejuez &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $72.00&#x7C;$102.00 &#x7C; 
&#x7C;Cristina Fernandez &#x7C;Telsey Advisory Group&#x7C;Maintains &#x7C;Market Perform &#x7C; $80.00&#x7C;$80.00 &#x7C; 
&#x7C;Simeon Siegel &#x7C;BMO Capital &#x7C;Raises &#x7C;Outperform &#x7C; $95.00&#x7C;$92.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Nike. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nike compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Nike's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NKE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Nike analyst ratings.</a>
<h2>Get to Know Nike Better</h2>
Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.
<h3>Nike: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Decline in Revenue: Over the 3M period, Nike faced challenges, resulting in a decline of approximately -9.33% in revenue growth as of 28 February, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Nike's net margin is impressive, surpassing industry averages. With a net margin of 7.05%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Nike's ROE excels beyond industry benchmarks, reaching 5.66%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Nike's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.1%, the company showcases efficient use of assets and strong financial health.
Debt Management: Nike's debt-to-equity ratio stands notably higher than the industry average, reaching 0.85. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What Analysts Are Saying About Nike Stock

Ratings for Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $119.89, along with a high estimate of $163.00 and a low estimate of $77.00. A 13.59% drop is evident in the current average compared to the previous average price target of $138.75. 
<img src="https://www.benzinga.com/files/images/story/2025/1745269251_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Global Payments. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Andrew Bauch &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $77.00&#x7C;$105.00 &#x7C; 
&#x7C;David Koning &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $100.00&#x7C;$145.00 &#x7C; 
&#x7C;Ramsey El-Assal &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $110.00&#x7C;$125.00 &#x7C; 
&#x7C;Adam Frisch &#x7C;Evercore ISI Group &#x7C;Announces &#x7C;In-Line &#x7C; $85.00&#x7C;- &#x7C; 
&#x7C;Vasundhara Govil &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Outperform &#x7C; $135.00&#x7C;$140.00 &#x7C; 
&#x7C;Ashwin Shirvaikar &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $135.00&#x7C;$138.00 &#x7C; 
&#x7C;Ramsey El-Assal &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $125.00&#x7C;$135.00 &#x7C; 
&#x7C;James Faucette &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $163.00&#x7C;$166.00 &#x7C; 
&#x7C;Jason Kupferberg &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $149.00&#x7C;$156.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Global Payments. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Global Payments compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Global Payments's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Global Payments's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GPN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Global Payments analyst ratings.</a>
<h2>Unveiling the Story Behind Global Payments</h2>
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares. The merger added issuer processing operations.
<h3>Global Payments: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Global Payments displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.35%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Global Payments's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 22.55% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Global Payments's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.52%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Global Payments's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 1.17%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Global Payments's debt-to-equity ratio is below the industry average. With a ratio of 0.75, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Global Payments Stock: Analyst Perspectives (9 Ratings)

Throughout the last three months, 30 analysts have evaluated ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">11</td>
<td align="right">15</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated ServiceNow and provided 12-month price targets. The average target is $1103.13, accompanied by a high estimate of $1432.00 and a low estimate of $716.00. Experiencing a 6.21% decline, the current average is now lower than the previous average price target of $1176.21. 
<img src="https://www.benzinga.com/files/images/story/2025/1745269243_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive ServiceNow. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;------------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Raimo Lenschow &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $967.00&#x7C;$1200.00 &#x7C; 
&#x7C;Keith Weiss &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $881.00&#x7C;$960.00 &#x7C; 
&#x7C;Thomas Blakey &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $1048.00&#x7C;$1048.00 &#x7C; 
&#x7C;John Difucci &#x7C;Guggenheim &#x7C;Maintains &#x7C;Sell &#x7C; $716.00&#x7C;$716.00 &#x7C; 
&#x7C;Brad Sills &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $1025.00&#x7C;$1280.00 &#x7C; 
&#x7C;Samad Samana &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $1025.00&#x7C;$1250.00 &#x7C; 
&#x7C;Michael Turrin &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $1100.00&#x7C;$1250.00 &#x7C; 
&#x7C;Kash Rangan &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $1050.00&#x7C;$1200.00 &#x7C; 
&#x7C;Robert Majek &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $1000.00&#x7C;$1200.00 &#x7C; 
&#x7C;Keith Bachman &#x7C;BMO Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $990.00&#x7C;$1185.00 &#x7C; 
&#x7C;Brad Reback &#x7C;Stifel &#x7C;Lowers &#x7C;Buy &#x7C; $950.00&#x7C;$1175.00 &#x7C; 
&#x7C;Joel Fishbein &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $950.00&#x7C;$1100.00 &#x7C; 
&#x7C;Rob Oliver &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $1010.00&#x7C;$1200.00 &#x7C; 
&#x7C;Gregg Moskowitz &#x7C;Mizuho &#x7C;Lowers &#x7C;Outperform &#x7C; $1100.00&#x7C;$1210.00 &#x7C; 
&#x7C;Thomas Blakey &#x7C;Cantor Fitzgerald &#x7C;Maintains &#x7C;Overweight &#x7C; $1048.00&#x7C;$1048.00 &#x7C; 
&#x7C;Karl Keirstead &#x7C;UBS &#x7C;Lowers &#x7C;Buy &#x7C; $1000.00&#x7C;$1250.00 &#x7C; 
&#x7C;Patrick Walravens &#x7C;Citizens Capital Markets&#x7C;Maintains &#x7C;Market Outperform&#x7C; $1300.00&#x7C;$1300.00 &#x7C; 
&#x7C;David Hynes &#x7C;Canaccord Genuity &#x7C;Maintains &#x7C;Buy &#x7C; $1275.00&#x7C;$1275.00 &#x7C; 
&#x7C;Tyler Radke &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $1426.00&#x7C;$1432.00 &#x7C; 
&#x7C;Samad Samana &#x7C;Jefferies &#x7C;Lowers &#x7C;Buy &#x7C; $1250.00&#x7C;$1300.00 &#x7C; 
&#x7C;David Hynes &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $1275.00&#x7C;$1200.00 &#x7C; 
&#x7C;Brian Schwartz &#x7C;Oppenheimer &#x7C;Raises &#x7C;Outperform &#x7C; $1200.00&#x7C;$1150.00 &#x7C; 
&#x7C;Matthew Hedberg &#x7C;RBC Capital &#x7C;Maintains &#x7C;Outperform &#x7C; $1210.00&#x7C;$1210.00 &#x7C; 
&#x7C;Rob Oliver &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $1200.00&#x7C;$1250.00 &#x7C; 
&#x7C;Mark Murphy &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $1200.00&#x7C;$1250.00 &#x7C; 
&#x7C;Patrick Walravens &#x7C;JMP Securities &#x7C;Maintains &#x7C;Market Outperform&#x7C; $1300.00&#x7C;$1300.00 &#x7C; 
&#x7C;Mike Cikos &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $1200.00&#x7C;$1150.00 &#x7C; 
&#x7C;Mark Murphy &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $1250.00&#x7C;$950.00 &#x7C; 
&#x7C;Tyler Radke &#x7C;Citigroup &#x7C;Raises &#x7C;Buy &#x7C; $1432.00&#x7C;$1071.00 &#x7C; 
&#x7C;John Difucci &#x7C;Guggenheim &#x7C;Announces &#x7C;Sell &#x7C; $716.00&#x7C;- &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ServiceNow. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of ServiceNow compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for ServiceNow's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of ServiceNow's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NOW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ServiceNow analyst ratings.</a>
<h2>Discovering ServiceNow: A Closer Look</h2>
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
<h3>Financial Insights: ServiceNow</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, ServiceNow showcased positive performance, achieving a revenue growth rate of 21.34% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 12.99%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): ServiceNow's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 4.06%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): ServiceNow's ROA excels beyond industry benchmarks, reaching 1.98%. This signifies efficient management of assets and strong financial health.
Debt Management: ServiceNow's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.24.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down ServiceNow: 30 Analysts Share Their Views

9 analysts have expressed a variety of opinions on Huntington Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBAN#NASDAQ">HBAN</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $17.78, a high estimate of $20.00, and a low estimate of $16.00. This current average has decreased by 6.72% from the previous average price target of $19.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1745269235_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Huntington Bancshares is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Karl Shepard &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $18.00&#x7C;$20.00 &#x7C; 
&#x7C;David Konrad &#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Market Perform &#x7C; $17.00&#x7C;$18.00 &#x7C; 
&#x7C;Terry McEvoy &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $16.50&#x7C;$16.50 &#x7C; 
&#x7C;David Long &#x7C;Raymond James &#x7C;Lowers &#x7C;Strong Buy &#x7C; $18.00&#x7C;$20.00 &#x7C; 
&#x7C;Andrew Dietrich &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $16.00&#x7C;$18.50 &#x7C; 
&#x7C;Keith Horowitz &#x7C;Citigroup &#x7C;Lowers &#x7C;Buy &#x7C; $18.00&#x7C;$20.00 &#x7C; 
&#x7C;Manan Gosalia &#x7C;Morgan Stanley &#x7C;Lowers &#x7C;Overweight &#x7C; $20.00&#x7C;$22.00 &#x7C; 
&#x7C;David George &#x7C;Baird &#x7C;Maintains &#x7C;Outperform &#x7C; $18.00&#x7C;$18.00 &#x7C; 
&#x7C;Terry McEvoy &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Equal-Weight &#x7C; $18.50&#x7C;$18.50 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Huntington Bancshares. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Huntington Bancshares compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Huntington Bancshares's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Huntington Bancshares's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HBAN/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Huntington Bancshares analyst ratings.</a>
<h2>Delving into Huntington Bancshares's Background</h2>
Huntington is a regional US bank with around $200 billion in assets (as of 2024) and has a large presence, particularly in the Midwestern market. It offers a full suite of consumer deposit and lending services, along with commercial services focused on payments, investment management, capital markets, equipment financing, treasury management, and other common banking services.
<h3>Huntington Bancshares's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Challenges: Huntington Bancshares's revenue growth over 3M faced difficulties. As of 31 March, 2025, the company experienced a decline of approximately -1.74%. This indicates a decrease in top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Huntington Bancshares's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 26.04%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Huntington Bancshares's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.76% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Huntington Bancshares's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.24%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Huntington Bancshares's debt-to-equity ratio surpasses industry norms, standing at 1.02. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HBAN

Breaking Down Huntington Bancshares: 9 Analysts Share Their Views

Analysts' ratings for Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) over the last quarter vary from bullish to bearish, as provided by 5 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Baidu, revealing an average target of $110.0, a high estimate of $130.00, and a low estimate of $90.00. Witnessing a positive shift, the current average has risen by 3.19% from the previous average price target of $106.60.
<img src="https://www.benzinga.com/files/images/story/2025/1745269227_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Baidu by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jiong Shao &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $90.00&#x7C;$95.00 &#x7C; 
&#x7C;Fawne Jiang &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $130.00&#x7C;$130.00 &#x7C; 
&#x7C;James Lee &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $105.00&#x7C;$95.00 &#x7C; 
&#x7C;Jiong Shao &#x7C;Barclays &#x7C;Raises &#x7C;Equal-Weight &#x7C; $95.00&#x7C;$83.00 &#x7C; 
&#x7C;Fawne Jiang &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $130.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Baidu. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Baidu compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Baidu's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Baidu's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/BIDU/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Baidu analyst ratings.</a>
<h2>Discovering Baidu: A Closer Look</h2>
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
<h3>Unraveling the Financial Story of Baidu</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Baidu faced challenges, resulting in a decline of approximately -2.37% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Net Margin: Baidu's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 13.49%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Baidu's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.76%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Baidu's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.09%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Baidu's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.3.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIDU

What Analysts Are Saying About Baidu Stock

In the latest quarter, 4 analysts provided ratings for ATI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for ATI, revealing an average target of $77.5, a high estimate of $81.00, and a low estimate of $73.00. Marking an increase of 2.99%, the current average surpasses the previous average price target of $75.25. 
<img src="https://www.benzinga.com/files/images/story/2025/1745269220_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of ATI among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Josh Sullivan &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $81.00&#x7C;$81.00 &#x7C; 
&#x7C;Josh Sullivan &#x7C;Benchmark &#x7C;Raises &#x7C;Buy &#x7C; $81.00&#x7C;$80.00 &#x7C; 
&#x7C;David Strauss &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $75.00&#x7C;$70.00 &#x7C; 
&#x7C;Charles Minervino &#x7C;Susquehanna &#x7C;Raises &#x7C;Positive &#x7C; $73.00&#x7C;$70.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to ATI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ATI compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of ATI's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into ATI's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/ATI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ATI analyst ratings.</a>
<h2>About ATI</h2>
ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace &amp; defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.
<h3>ATI: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining ATI's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.22% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: ATI's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 11.69%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): ATI's ROE stands out, surpassing industry averages. With an impressive ROE of 7.53%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): ATI's ROA stands out, surpassing industry averages. With an impressive ROA of 2.66%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: ATI's debt-to-equity ratio surpasses industry norms, standing at 1.02. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where ATI Stands With Analysts

Press Releases

MAIA Biotechnology to Present at Biotech Showcase 2025

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Announces Private Placement of $2,715,000

MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients

MAIA Biotechnology Receives USAN Council Approval for "Ateganosine" as Nonproprietary Name for Anticancer Agent THIO

MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug

MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders

MAIA

Adicet Bio

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Armata Pharmaceuticals, Inc. Common Stock

Armata Pharmaceuticals

Avalo Therapeutics

Citius Oncology

Fortress Biotech

FibroBiologics

Forte Biosciences

Gain Therapeutics

ImmuCell

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Mural Oncology

Outlook Therapeutics, Inc. - Common Stock

Outlook Therapeutics

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PepGen

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Quince Therapeutics

Repare Therapeutics

Skye Bioscience

Sutro Biopharma

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Noble Capital Markets

Screenshot 2024-09-10 at 8.49.39 PM

REGN

MAIA Biotechnology&#39;s Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

Screenshot 2024-06-06 at 5.43.20 PM

New Clinical Data Reveals MAIA Biotechnology&#39;s THIO Achieves High Efficacy In Advanced Non-Small Cell Lung Cancer Treatment

Screenshot 2024-05-21 at 5.35.44 PM

MAIA Biotechnology&#39;s Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market

Screenshot 2024-02-28 at 6.41.05 PM

MAIA Biotech Completes Enrollment For Phase 2 Trial Of Its Candidate THIO To Fight Non-Small Cell Lung Cancer

Comments

MAIA Biotechnology

MAIA Biotechnology (MAIA) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO